Skip to main content
. Author manuscript; available in PMC: 2015 May 7.
Published in final edited form as: JAMA Intern Med. 2014 Mar;174(3):324–333. doi: 10.1001/jamainternmed.2013.13656

Table 2.

Adjusted Means for 40-Month TBV by Blood Pressure and Lipid Trials

Trial Therapy Group No. of
Participants
Baseline Mean
TBV, cm3a
TBV, Mean (95% CI), cm3b P Valuec
40 mo Change From Baseline
Blood pressure INT 153 921.5 902.6 (900.2 to 905.0) −18.9 (−21.3 to −16.5)
STD 161 921.5 907.0 (904.7 to 909.4) −14.5 (−16.8 to −12.2)
40-mo difference −4.4 (−7.8 to −1.1) .01
Lipid Fenofibrate 89 937.0 924.1 (920.9 to 927.2) −12.9 (−16.1 to −9.8)
Placebo 100 937.0 922.9 (919.9 to 925.9) −14.1 (−17.1 to −11.1)
40-mo difference 1.2 (−3.1 to 5.5) .59

Abbreviations: INT, intensive; STD, standard; TBV, total brain volume.

a

Baseline mean is the overall mean for both groups combined as measured before randomization. This value is used to obtain the adjusted mean estimates at follow-up.

b

Indicates adjusted mean obtained from analysis of covariance.

c

Calculated as a test of difference between the intervention group means at the 40-month visit, adjusted for the baseline level of the outcome. When controlling for the baseline value of the outcome, the P value for a comparison of the 40-month means between intervention groups will be identical to the P value for a comparison of change from baseline (controlling for the baseline level as a covariate) to the 40-month visit.